Cullinan Oncology to present data across immunotherapy pipeline

Cullinan Oncology will present data across four distinct immuno-oncology programs in five poster presentations at the Society for Immunotherapy of Cancer 2023 Annual Meeting taking place November 1-5 in San Diego. Title: Characterization of the pharmacodynamic activity of CLN-619, an anti-MICA/B monoclonal antibody, in patients from an ongoing Phase 1 trial: Initial clinical biomarker data demonstrates that CLN-619 increases MICA expression on the tumor cell surface, consistent with previously reported preclinical data and supporting the proposed mechanism of action. Data from patients with available biopsy data demonstrate clinical benefit, including objective response, in patients with tumors with characteristics not typically responsive to checkpoint inhibitor therapy. Specifically, tumors from two patients with endometrial cancer and previously reported confirmed partial responses were microsatellite stable, had low tumor mutational burden, and low neoantigen presentation index. Available biopsies from patients with prolonged stable disease showed similar low mutational burden and neoantigen presentation index characteristics, as well as increased surface MICA/B expression and NK cell activation.